{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:05:25Z","timestamp":1792209925384,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jacadv.2025.101876","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T07:48:12Z","timestamp":1750664892000},"page":"101876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Benefits of Patisiran on Functional Capacity in ATTR Cardiac Amyloidosis"],"prefix":"10.1016","volume":"4","author":[{"given":"John L.","family":"Berk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8141-6582","authenticated-orcid":false,"given":"Olivier","family":"Lairez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Schwartzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y.","family":"Jay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2025.101876_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.101876_bib2","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.101876_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.jacadv.2025.101876_bib4","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1136\/heartjnl-2012-301924","article-title":"Cardiac transthyretin amyloidosis","volume":"98","author":"Dungu","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.jacadv.2025.101876_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40119-023-00344-3","article-title":"Clinical and genotype characteristics and symptom migration in patients with mixed phenotype transthyretin amyloidosis from the Transthyretin Amyloidosis Outcomes Survey","volume":"13","author":"Gonzalez-Moreno","year":"2023","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.jacadv.2025.101876_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101876_bib7","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/ehf2.13541","article-title":"Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT","volume":"8","author":"Nativi-Nicolau","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacadv.2025.101876_bib8","first-page":"442","article-title":"Prognosis of transthyretin cardiac amyloidosis without heart failure symptoms","volume":"4","author":"Gonzalez-Lopez","year":"2022","journal-title":"JACC"},{"key":"10.1016\/j.jacadv.2025.101876_bib9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacadv.2025.101876_bib10","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"46","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.jacadv.2025.101876_bib11","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.amjcard.2022.10.014","article-title":"Overview of current and emerging therapies for amyloid transthyretin cardiomyopathy","volume":"185","author":"Maurer","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2025.101876_bib12","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.101876_bib13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/bmj.2.5402.177","article-title":"Human experimentation. Code of ethics of the World Medical Association. Declaration of Helsinki","volume":"2","author":"Rickham","year":"1964","journal-title":"Br Med J"},{"key":"10.1016\/j.jacadv.2025.101876_bib14","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","article-title":"Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC State-of-the-Art Review","volume":"76","author":"Spertus","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.101876_bib15","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/CIRCULATIONAHA.108.820472","article-title":"Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS)","volume":"119","author":"Chan","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.101876_bib16","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/jamacardio.2017.3983","article-title":"Association of Serial Kansas City Cardiomyopathy questionnaire assessments with death and hospitalization in patients with heart failure with preserved and reduced ejection fraction: a secondary analysis of 2 randomized clinical trials","volume":"2","author":"Pokharel","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2025.101876_bib17","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ahj.2004.12.010","article-title":"Monitoring clinical changes in patients with heart failure: a comparison of methods","volume":"150","author":"Spertus","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacadv.2025.101876_bib18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.cardfail.2006.04.004","article-title":"Association of functional and health status measures in heart failure","volume":"12","author":"Myers","year":"2006","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacadv.2025.101876_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2318-7-13","article-title":"Predicting nursing home admission in the U.S: a meta-analysis","volume":"7","author":"Gaugler","year":"2007","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.jacadv.2025.101876_bib20","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jacc.2024.11.015","article-title":"Outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial","volume":"85","author":"Fontana","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.101876_bib21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jacc.2024.04.011","article-title":"Prognostic value of a 6-minute walk test in patients with transthyretin cardiac amyloidosis","volume":"84","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.101876_bib22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/jep.12629","article-title":"Minimal clinically important difference for change in 6-minute walk test distance of adults with pathology: a systematic review","volume":"23","author":"Bohannon","year":"2017","journal-title":"J Eval Clin Pract"},{"key":"10.1016\/j.jacadv.2025.101876_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13023-017-0633-1","article-title":"Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome","volume":"12","author":"Schrover","year":"2017","journal-title":"Orphanet J Rare Dis"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25002960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25002960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T18:20:56Z","timestamp":1773166856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25002960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2772963X25002960"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101876","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefits of Patisiran on Functional Capacity in ATTR Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.101876","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101876"}}